We are live on
!
Find out more
PA
Perceptive Advisors Portfolio holdings
AUM
$5.12B
1-Year Est. Return
314.02%
This Fund
S&P 500
This Quarter
Est. Return
-8.37%
1 Year Est. Return
+314.02%
3 Year Est. Return
+1,498.66%
5 Year Est. Return
+2,457.67%
10 Year Est. Return
+48,821.41%
AUM
$3.71B
AUM Growth
-$646M
(-15%)
Cap. Flow
+$138M
Cap. Flow
% of AUM
3.73%
Top 10 Holdings %
Top 10 Hldgs %
52.04%
Holding
130
New
26
Increased
23
Reduced
15
Closed
21
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
SWTX
SpringWorks Therapeutics
SWTX
|
+$76.1M |
| 2 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
+$38.9M |
| 3 |
FOLD
Amicus Therapeutics
FOLD
|
+$33.6M |
| 4 |
AMRN
Amarin Corp
AMRN
|
+$25M |
| 5 |
YMAB
Y-mAbs Therapeutics
YMAB
|
+$21.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Ascendis Pharma A/S
ASND
|
+$54.5M |
| 2 |
ARRY
Array Biopharma Inc
ARRY
|
+$48.1M |
| 3 |
BPMC
Blueprint Medicines
BPMC
|
+$28.5M |
| 4 |
ARNA
Arena Pharmaceuticals Inc
ARNA
|
+$24M |
| 5 |
uniQure
QURE
|
+$22M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 93.8% |
| 2 | Financials | 0.46% |
| 3 | Consumer Discretionary | 0.18% |
| 4 | Technology | 0.07% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Neurocrine Biosciences
NBIX
$18.3B
| $366M | 9.86% |
4,059,900
+36,038
| +0.9% | +$3.37M |
|
|
GBT
2
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $285M | 7.68% |
5,875,726
+100,000
| +2% | +$5.21M |
|
|
MRTX
3
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $258M | 6.96% |
3,314,606
+415,000
| +14% | +$38.9M |
|
4
Iovance Biotherapeutics
IOVA
$2.04B
| $200M | 5.4% |
11,014,702
-900,425
| -8% | -$19.9M |
|
|
FOLD
5
DELISTED
Amicus Therapeutics
FOLD
| $197M | 5.32% |
24,609,700
+3,100,214
| +14% | +$33.6M |
|
6
BridgeBio Pharma
BBIO
$16.6B
| $144M | 3.88% |
6,706,268
| – | – |
|
|
ZGNX
7
DELISTED
Zogenix, Inc.
ZGNX
| $131M | 3.52% |
3,264,152
-243,071
| -7% | -$11.2M |
|
|
ATNX
8
DELISTED
Athenex, Inc. Common Stock
ATNX
| $131M | 3.52% |
536,762
+45,656
| +9% | +$14.9M |
|
|
AMRN
9
Amarin Corp
AMRN
$298M
| $116M | 3.12% |
381,804
+71,741
| +23% | +$25M |
|
|
DOVA
10
DELISTED
Dova Pharmaceuticals, Inc. Common Stock
DOVA
| $104M | 2.79% |
3,708,705
+155,645
| +4% | +$2.52M |
|
11
MeiraGTx Holdings
MGTX
$1.08B
| $103M | 2.76% |
6,433,277
+425,531
| +7% | +$9.9M |
|
|
QTNT
12
DELISTED
Quotient Limited Ordinary Shares
QTNT
| $83.8M | 2.26% |
269,726
| – | – |
|
|
NVRO
13
DELISTED
NEVRO CORP.
NVRO
| $83.8M | 2.26% |
974,773
-162,992
| -14% | -$12.3M |
|
14
Solid Biosciences
SLDB
$794M
| $69.8M | 1.88% |
449,987
+188,172
| +72% | +$21.3M |
|
|
SWTX
15
DELISTED
SpringWorks Therapeutics
SWTX
| $69.8M | 1.88% |
+3,217,522
| New | +$76.1M |
|
|
BPMC
16
DELISTED
Blueprint Medicines
BPMC
| $64.9M | 1.75% |
883,264
-329,467
| -27% | -$28.5M |
|
17
Zymeworks
ZYME
$1.63B
| $59.2M | 1.6% |
2,388,890
+20,000
| +0.8% | +$501K |
|
|
MYOK
18
DELISTED
MyoKardia, Inc. Common Stock
MYOK
| $59M | 1.59% |
1,130,511
+30,000
| +3% | +$1.6M |
|
19
ADMA Biologics
ADMA
$2.02B
| $51.3M | 1.38% |
11,521,102
| – | – |
|
20
Verrica Pharmaceuticals
VRCA
$92.9M
| $50.3M | 1.36% |
341,041
| – | – |
|
|
NEPT
21
DELISTED
Neptune Wellness Solutions Inc. Ordinary Shares
NEPT
| $47.8M | 1.29% |
9,598
+3,247
| +51% | +$21.1M |
|
|
VBIV
22
DELISTED
VBI Vaccines, Inc. New Common Stock (Canada)
VBIV
| $46M | 1.24% |
1,531,719
+666,667
| +77% | +$14M |
|
23
Kodiak Sciences
KOD
$2.44B
| $45.1M | 1.21% |
3,135,199
| – | – |
|
|
ARNA
24
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $43.6M | 1.18% |
953,129
-427,042
| -31% | -$24M |
|
25
Allogene Therapeutics
ALLO
$583M
| $42.1M | 1.13% |
1,543,790
| – | – |
|
Similar funds
BG
TAM
CIA
AC
EIC
CIC
CS
NC
Perceptive Advisors's Q3 2019 Portfolio in Review
As of Q3 2019, Perceptive Advisors held 130 positions worth $3.71B, down 15% from $4.36B the previous quarter. Its ten largest holdings account for 52% of the portfolio.
Perceptive Advisors deployed $138M of net new capital in Q3 2019, opening 26 new positions and adding to 23 existing holdings. Its largest new stake was SpringWorks Therapeutics: 3,217,522 shares worth $69.8M.
By sector, the portfolio is most concentrated in Healthcare at 94% of assets, up from 94% a quarter earlier, followed by Financials and Consumer Discretionary.
On the sell side, the largest reduction was Blueprint Medicines, an estimated $28.5M trimmed.
- Perceptive Advisors's largest Q3 2019 buy was SpringWorks Therapeutics: 3,217,522 shares worth $69.8M.
- Perceptive Advisors added most to Mirati Therapeutics, Inc. Common Stock in Q3 2019, an estimated $38.9M increase.
- Perceptive Advisors's biggest Q3 2019 reduction was Blueprint Medicines, cutting an estimated $28.5M.
- Perceptive Advisors fully exited Ascendis Pharma A/S in Q3 2019, selling an estimated $54.5M.
- Perceptive Advisors's ten largest holdings make up 52% of its $3.71B portfolio in Q3 2019.
- Perceptive Advisors opened 26 new positions and closed 21 in Q3 2019.
- Perceptive Advisors's portfolio value fell 15% quarter-over-quarter to $3.71B.
Based on Perceptive Advisors's 13F filing for Q3 2019, filed 14 Nov 2019.